Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, \>/= 18 years of age~* Patients with rheumatoid arthritis for whom the rheumatologist decides to start tocilizumab in combination with DMARD or as monotherapy~Exclusion Criteria:~* Current participation in a clinical trial in rheumatoid arthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: None): Tocilizumab administered as monotherapy or in combination with other standard of care therapy according to prescribing information and normal clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).